The pharmaceutical company Myungin Pharmaceutical, which produces the gum disease treatment "Igatang," is challenging to be listed on the KOSPI.
According to the Korea Exchange on the 30th, Myungin Pharmaceutical submitted its listing preliminary review application to the Korea Exchange's securities market headquarters on this day. KB Securities is serving as the lead underwriter.
Myungin Pharmaceutical was established in 1988 as a manufacturer of prescription and over-the-counter medications. It has grown into a mid-sized pharmaceutical company with annual sales of 270 billion won, led by "Igatang."
For the previous year, sales amounted to 269.6 billion won, and operating profit recorded 90.1 billion won. Currently, CEO Lee Haeng-myung is the largest shareholder, holding 66.32% of the equity.